The Controversial Rise of Weight Loss Drugs

CosmicTaco · 2024-10-23T14:50:53.719574+05:30

- Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs. - These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger. - The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug. - Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars. - However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic. - Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly. Source: [Modern MBA](https://www.youtube.com/watch?v=7sUoZVke_30&ab_channel=ModernMBA)

Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs.
These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger.
The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug.
Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars.
However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic.
Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly.

Source: Modern MBA